Alpha 2.0
Login Register
» Authors » Razvan Cristescu

Razvan Cristescu

Explore the profile of Razvan Cristescu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 52
Citations 4744
Followers 0
Related Specialties
Oncology
Allergy & Immunology
Molecular Biology
Top 10 Co-Authors
Andrey Loboda
Michael Nebozhyn
Jared Lunceford
Jeeyun Lee
Cai Chen
Mark Ayers
Changxia Shao
Xiao Qiao Liu
I-Ming Wang
Lingkang Huang
Published In
J Immunother Cancer
Clin Cancer Res
Nat Med
Mol Cancer Ther
Gynecol Oncol
Affiliations
Soon will be listed here.
Recent Articles
11.
Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases
Shui I, Burcu M, Shao C, Chen C, Liao C, Jiang S, et al.
Prostate Cancer Prostatic Dis . 2023 Dec; 27(4):728-735. PMID: 38057611
Background: Homologous recombination repair mutation (HRRm) status may guide risk-stratification and treatment decisions, including polyadenosine diphosphate-ribose polymerase inhibitor use, in advanced prostate cancer. Although HRRm prevalence has been reported in...
12.
Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors
Shao C, Ren Y, Zhou H, Chen C, Dettman E, Lee L, et al.
JCO Precis Oncol . 2023 Nov; 7:e2300195. PMID: 37972338
Purpose: Mutations in and/or (BRCAm), other homologous recombination repair genes (HRRm), and homologous recombination deficiency (HRD) lead to an accumulation of genomic alterations that can drive tumorigenesis. The prognostic impact...
13.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Ledermann J, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I, et al.
Gynecol Oncol . 2023 Oct; 178:119-129. PMID: 37862791
Objective: This prespecified exploratory analysis evaluated the association of gene expression signatures, tumor mutational burden (TMB), and multiplex immunohistochemistry (mIHC) tumor microenvironment-associated cell phenotypes with clinical outcomes of pembrolizumab in...
14.
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Gutierrez M, Lam W, Hellmann M, Gubens M, Aggarwal C, Tan D, et al.
Nat Med . 2023 Jul; 29(7):1718-1727. PMID: 37429923
Although pembrolizumab confers clinical benefit in non-small cell lung cancer (NSCLC), only a subset of patients will respond due to a heterogenous tumor microenvironment. KEYNOTE-495/KeyImPaCT is an ongoing biomarker-directed, adaptively...
15.
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
Shitara K, Di Bartolomeo M, Mandala M, Ryu M, Caglevic C, Olesinski T, et al.
J Immunother Cancer . 2023 Jul; 11(6). PMID: 37399357
Background: In the randomized, controlled, phase III KEYNOTE-061 trial, second-line pembrolizumab did not significantly prolong overall survival (OS) versus paclitaxel in patients with PD-L1-positive (combined positive score ≥1) advanced gastric/gastroesophageal...
16.
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
Loi S, Salgado R, Schmid P, Cortes J, Cescon D, Winer E, et al.
JCO Precis Oncol . 2023 Apr; 7:e2200317. PMID: 37099733
Purpose: In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254)....
17.
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
Garassino M, Gadgeel S, Novello S, Halmos B, Felip E, Speranza G, et al.
JTO Clin Res Rep . 2023 Feb; 4(1):100431. PMID: 36793385
Introduction: We evaluated tissue tumor mutational burden (tTMB) and mutations in and as biomarkers for outcomes with pembrolizumab plus platinum-based chemotherapy (pembrolizumab-combination) for NSCLC among patients in the phase 3...
18.
Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test
Cristescu R, Liu X, Arreaza G, Chen C, Albright A, Qiu P, et al.
BMC Cancer . 2022 Dec; 22(1):1310. PMID: 36517748
Background: We evaluated the performance of single-nucleotide polymorphism (SNP) genotyping arrays OncoScan (Thermo Fisher Scientific, San Diego, CA) and Infinium CytoSNP-850K (CytoSNP; Illumina, Waltham, MA) for assessing homologous recombination deficiency...
19.
Biomarkers predictive of response to pembrolizumab in head and neck cancer
Pfister D, Haddad R, Worden F, Weiss J, Mehra R, Chow L, et al.
Cancer Med . 2022 Dec; 12(6):6603-6614. PMID: 36479637
Background: We performed an integrated biomarker evaluation in pembrolizumab-treated patients with R/M HNSCC enrolled in KEYNOTE-012 or KEYNOTE-055. The relationship between biomarkers and HPV status was explored. Methods: We evaluated...
20.
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
Shui I, Liu X, Zhao Q, Kim S, Sun Y, Yearley J, et al.
J Immunother Cancer . 2022 Jul; 10(7). PMID: 35793874
Background: Immunotherapies targeting programmed cell death-1 (PD-1) and its ligands have improved clinical outcomes for advanced melanoma. However, many tumors exhibit primary resistance or acquire secondary resistance after an initial...